In Vitro Assessment Of Fc Functional Activity: A Broad Range Of Solutions For Diverse Assay Needs

The efficacy of numerous cancer therapies hinges on their ability to trigger Antibody-Dependent Cellular Cytotoxicity (ADCC), Antibody-Dependent Cellular Phagocytosis (ADCP), and Complement-Dependent Cytotoxicity (CDC) against targeted cells. Robust assessment of these functions is paramount before clinical trials. Equally important is demonstrating the absence of unintended effector functions to ensure safety.

This poster explores the key considerations for designing successful Fc effector function assays. We evaluate the advantages and limitations of various assay formats suited for different purposes. Additionally, we discuss strategies for selecting the most appropriate target cell lines, effector cells, and essential controls.

A thorough understanding of a drug candidate's mode of action (MoA), assay sensitivity, experimental complexity, and regulatory requirements is fundamental for all drug development programs. By employing a comprehensive panel of assays to characterize the Fc-mediated activity of antibodies, Fc fusion proteins, or antibody-drug conjugates (ADCs), researchers can streamline development and expedite the path to clinic.